Exact Mass: 411.1543

Exact Mass Matches: 411.1543

Found 70 metabolites which its exact mass value is equals to given mass value 411.1543, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

COELENTERAMIDE

Oxidized Oplophorus luciferin

C25H21N3O3 (411.1583)


   

Ro 18-5364

5,7-Dihydro-2-(((4-methoxy-3-methyl-2-pyridyl)methyl)sulfinyl)-5,5,7,7-tetramethylindeno(5,6-d)imidazol-6(1H)-one

C22H25N3O3S (411.1617)


   

N6-carbamoylthreonyladenosine

(2S,3R)-N-{9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-9H-purin-6-yl}-3-hydroxy-2-[(C-hydroxycarbonimidoyl)amino]butanimidate

C15H21N7O7 (411.1502)


N6-Carbamoyl-L-threonyladenosine is a member of the class of compounds known as purine nucleosides. Purine nucleosides are compounds composed of a purine base attached to a ribosyl or deoxyribosyl moiety. N6-Carbamoyl-L-threonyladenosine is slightly soluble (in water) and a very weakly acidic compound (based on its pKa). Within the cell, N6-carbamoyl-L-threonyladenosine is primarily located in the cytoplasm. It can also be found in the extracellular space. N6-Carbamoyl-L-threonyladenosine is a minor constituent found in human and bovine milk (PMID: 7702711). Minor constituant found in human, bovine, and goat milk

   

Magon

N-(2,4-dimethylphenyl)-3-hydroxy-4-[2-(2-hydroxyphenyl)diazen-1-yl]naphthalene-2-carboxamide

C25H21N3O3 (411.1583)


   

N-(2(S)-(Acetylthiomethyl)-3-(2-methylphenyl)-1-oxopropyl)-L-methionine ethyl ester

3-(Acetylsulphanyl)-N-[1-ethoxy-4-(methylsulphanyl)-1-oxobutan-2-yl]-2-[(2-methylphenyl)methyl]propanimidic acid

C20H29NO4S2 (411.1538)


   

Acetamide, N-(((5S)-3-(3-fluoro-4-(6-(1-methyl-1H-tetrazol-5-yl)-3-pyridinyl)phenyl)-2-oxo-5-oxazolidinyl)methyl)-

N-[(3-{3-fluoro-4-[6-(1-methyl-1H-1,2,3,4-tetrazol-5-yl)pyridin-3-yl]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]ethanimidate

C19H18FN7O3 (411.1455)


   
   

Threonylcarbamoyladenosine

Threonylcarbamoyladenosine

C15H21N7O7 (411.1502)


   
   
   
   
   
   
   
   
   
   
   
   

Threonyl carbamoyl adenosine

Threonyl carbamoyl adenosine

C15H21N7O7 (411.1502)


   
   
   
   
   
   
   
   
   
   

6-HydroxyKetanserin

6-HydroxyKetanserin

C22H22FN3O4 (411.1594)


   

3-Butyl-1,1,2-trimethyl-1H-benzo[e]indolium hexafluorophosphate

3-Butyl-1,1,2-trimethyl-1H-benzo[e]indolium hexafluorophosphate

C19H24F6NP (411.155)


   

4-Aminodibenzo-18-crown-6 hydrochloride

4-Aminodibenzo-18-crown-6 hydrochloride

C20H26ClNO6 (411.1449)


   

(2s,4s)-1-t-butoxycarbonyl-2-(N-T-butoxycarbonyl-N-sulfamoylamino)methyl-4-mercapto-pyrrolidine

(2s,4s)-1-t-butoxycarbonyl-2-(N-T-butoxycarbonyl-N-sulfamoylamino)methyl-4-mercapto-pyrrolidine

C15H29N3O6S2 (411.1498)


   

Methyl 1-((2-cyano-[1,1-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate

Methyl 1-((2-cyano-[1,1-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate

C25H21N3O3 (411.1583)


   

2-[(2-cyanoethyl)[4-[(2-hydroxy-4-nitrophenyl)azo]-m-tolyl]amino]ethyl acetate

2-[(2-cyanoethyl)[4-[(2-hydroxy-4-nitrophenyl)azo]-m-tolyl]amino]ethyl acetate

C20H21N5O5 (411.1543)


   

Bimiralisib

Bimiralisib

C17H20F3N7O2 (411.163)


C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C2152 - Phosphatidylinositide 3-Kinase Inhibitor C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor Bimiralisib (PQR309) is a potent, brain-penetrant, orally bioavailable, pan-class I PI3K/mTOR inhibitor with IC50s of 33 nM, 451 nM, 661 nM, 708 nM and 89 nM for PI3Kα, PI3Kδ, PI3Kβ, PI3Kγ and mTOR, respectively. Bimiralisib is an mTORC1 and mTORC2 inhibitor. Bimiralisib (PQR309) is a potent, brain-penetrant, orally bioavailable, pan-class I PI3K/mTOR inhibitor with IC50s of 33 nM, 451 nM, 661 nM, 708 nM and 89 nM for PI3Kα, PI3Kδ, PI3Kβ, PI3Kγ and mTOR, respectively. Bimiralisib is an mTORC1 and mTORC2 inhibitor.

   

Pizotifen maleate

Pizotifen maleate

C23H25NO4S (411.1504)


   

4-(dimethylsulfamoyl)-N-(6,7,8,9-tetrahydro-5H-carbazol-3-ylmethyl)benzamide

4-(dimethylsulfamoyl)-N-(6,7,8,9-tetrahydro-5H-carbazol-3-ylmethyl)benzamide

C22H25N3O3S (411.1617)


   

H-Glu-Thr-Tyr-OH

H-Glu-Thr-Tyr-OH

C18H25N3O8 (411.1642)


   

N-(2(S)-(Acetylthiomethyl)-3-(2-methylphenyl)-1-oxopropyl)-L-methionine ethyl ester

3-(Acetylsulphanyl)-N-[1-ethoxy-4-(methylsulphanyl)-1-oxobutan-2-yl]-2-[(2-methylphenyl)methyl]propanimidic acid

C20H29NO4S2 (411.1538)


   

4-hydroxy-rot-2-enonate

4-hydroxy-rot-2-enonate

C23H23O7- (411.1444)


   

5-Hydroxy-rot-2-enonate

5-Hydroxy-rot-2-enonate

C23H23O7- (411.1444)


   

N-[[3-[3-fluoro-4-[6-(1-methyltetrazol-5-yl)pyridin-3-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide

N-[[3-[3-fluoro-4-[6-(1-methyltetrazol-5-yl)pyridin-3-yl]phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide

C19H18FN7O3 (411.1455)


   

1-(5-tert-butyl-1,2-oxazol-3-yl)-3-[3-fluoro-4-(1H-pyrazolo[3,4-d]pyrimidin-4-yloxy)phenyl]urea

1-(5-tert-butyl-1,2-oxazol-3-yl)-3-[3-fluoro-4-(1H-pyrazolo[3,4-d]pyrimidin-4-yloxy)phenyl]urea

C19H18FN7O3 (411.1455)


   

2-(1,5-Dimethyl-3-oxo-2-phenyl-4-pyrazolyl)-3-hydroxy-3-phenyl-1-isoindolone

2-(1,5-Dimethyl-3-oxo-2-phenyl-4-pyrazolyl)-3-hydroxy-3-phenyl-1-isoindolone

C25H21N3O3 (411.1583)


   
   

N-(3,4-dimethylphenyl)-2-[[5-[3-(4-methoxyphenyl)propyl]-1,3,4-oxadiazol-2-yl]thio]acetamide

N-(3,4-dimethylphenyl)-2-[[5-[3-(4-methoxyphenyl)propyl]-1,3,4-oxadiazol-2-yl]thio]acetamide

C22H25N3O3S (411.1617)


   

(E)-3-(4-methoxyphenyl)-N-[4-(2-methoxyphenyl)piperazine-1-carbothioyl]prop-2-enamide

(E)-3-(4-methoxyphenyl)-N-[4-(2-methoxyphenyl)piperazine-1-carbothioyl]prop-2-enamide

C22H25N3O3S (411.1617)


   

5-(4-Ethoxyphenyl)-1,3-diphenyl-3a,6a-dihydropyrrolo[3,4-c]pyrazole-4,6-dione

5-(4-Ethoxyphenyl)-1,3-diphenyl-3a,6a-dihydropyrrolo[3,4-c]pyrazole-4,6-dione

C25H21N3O3 (411.1583)


   

2-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-2-oxoethyl]sulfanyl-6-ethyl-5-methylpyridine-3-carbonitrile

2-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-2-oxoethyl]sulfanyl-6-ethyl-5-methylpyridine-3-carbonitrile

C22H25N3O3S (411.1617)


   

6-(7,8-dimethoxy-1-methyl-3-phenyl-2H-pyrazolo[3,4-c]isoquinolin-5-ylidene)-1-cyclohexa-2,4-dienone

6-(7,8-dimethoxy-1-methyl-3-phenyl-2H-pyrazolo[3,4-c]isoquinolin-5-ylidene)-1-cyclohexa-2,4-dienone

C25H21N3O3 (411.1583)


   
   
   
   
   
   
   
   
   
   
   

2-(4-(4-Methoxyphenyl)-6-phenyl-2-pyrimidinylamino)benzoic acid methyl ester

2-(4-(4-Methoxyphenyl)-6-phenyl-2-pyrimidinylamino)benzoic acid methyl ester

C25H21N3O3 (411.1583)


   

2,4-Dibenzyl-4,4A-dihydro-1H-(1,3,5)triazino(1,2-A)quinoline-1,3,6(2H,5H)-trione

2,4-Dibenzyl-4,4A-dihydro-1H-(1,3,5)triazino(1,2-A)quinoline-1,3,6(2H,5H)-trione

C25H21N3O3 (411.1583)


   
   

E-3620

E-3620

C20H27Cl2N3O2 (411.148)


E-3620 is a potent 5-HT3 receptor antagonist. E-3620 can be used for the research of dyskinesi and gastrointestinal motility[1][2].

   

3-[(1s)-1-[(5r)-6-hydroxy-5-[(methylsulfanyl)methyl]-3-[(1e)-2-oxocyclopent-3-en-1-ylidene]-4,5-dihydro-2h-pyrazin-2-yl]ethyl]-1-methyl-3h-indol-2-one

3-[(1s)-1-[(5r)-6-hydroxy-5-[(methylsulfanyl)methyl]-3-[(1e)-2-oxocyclopent-3-en-1-ylidene]-4,5-dihydro-2h-pyrazin-2-yl]ethyl]-1-methyl-3h-indol-2-one

C22H25N3O3S (411.1617)


   

(3s)-3-[(1s)-1-[(2s,5r)-6-hydroxy-5-[(methylsulfanyl)methyl]-3-[(1z)-2-oxocyclopent-3-en-1-ylidene]-4,5-dihydro-2h-pyrazin-2-yl]ethyl]-1-methyl-3h-indol-2-one

(3s)-3-[(1s)-1-[(2s,5r)-6-hydroxy-5-[(methylsulfanyl)methyl]-3-[(1z)-2-oxocyclopent-3-en-1-ylidene]-4,5-dihydro-2h-pyrazin-2-yl]ethyl]-1-methyl-3h-indol-2-one

C22H25N3O3S (411.1617)


   

6-[2-(1,5-dihydroxy-5-methylhexyl)-1,3-thiazol-4-yl]-3-hydroxy-4,5-dimethoxypyridine-2-carboximidic acid

6-[2-(1,5-dihydroxy-5-methylhexyl)-1,3-thiazol-4-yl]-3-hydroxy-4,5-dimethoxypyridine-2-carboximidic acid

C18H25N3O6S (411.1464)


   

3-(1-{6-hydroxy-5-[(methylsulfanyl)methyl]-3-(2-oxocyclopent-3-en-1-ylidene)-4,5-dihydro-2h-pyrazin-2-yl}ethyl)-1-methyl-3h-indol-2-one

3-(1-{6-hydroxy-5-[(methylsulfanyl)methyl]-3-(2-oxocyclopent-3-en-1-ylidene)-4,5-dihydro-2h-pyrazin-2-yl}ethyl)-1-methyl-3h-indol-2-one

C22H25N3O3S (411.1617)


   

(3s)-3-[(1s)-1-[(2s,5r)-6-hydroxy-5-[(methylsulfanyl)methyl]-3-[(1e)-2-oxocyclopent-3-en-1-ylidene]-4,5-dihydro-2h-pyrazin-2-yl]ethyl]-1-methyl-3h-indol-2-one

(3s)-3-[(1s)-1-[(2s,5r)-6-hydroxy-5-[(methylsulfanyl)methyl]-3-[(1e)-2-oxocyclopent-3-en-1-ylidene]-4,5-dihydro-2h-pyrazin-2-yl]ethyl]-1-methyl-3h-indol-2-one

C22H25N3O3S (411.1617)